Summary The present study examines the relationship between neuroendocrine (NE) differentiation and the clinical behaviour of non-small cell lung cancer (NSCLC). Retrospective (n = 315) and prospective (n = 44) cohorts of non-small cell tumours were obtained from surgically treated cases of lung cancer, comprising 218 squamous cell carcinomas, 65 adenocarcinomas, 51 adenosquamous carcinomas, and 25 large cell undifferentiated carcinomas. Paraffin wax embedded and fresh frozen tissue sections were stained for the NE markers neurone specific enolase, creatine kinase-BB, bombesin, neurotensin, chromogranin A, synaptophysin and UJ-13A. The expression of two or more markers was observed in 30% of cases, and was taken to identify NE-NSCLC. A statistically significant correlation between nodal status and NE differentiation (P = 0.05), and disease stage and NE differentiation (P = 0.04) was observed. However, there was no correlation between NE differentiation and survival. These findings suggest that NE-NSCLC, analogous to SCLC is more highly metastatic than non-NE-NSCLC.
A number of studies have demonstrated the presence of neuroendocrine (NE) markers in non-small cell lung cancer (NSCLC) . These include L-dopa decarboxylase (Baylin et al., 1980; Berger et al., 1981; Gazdar et al., 1988a) , peptide hormones including calcitonin (Berger et al., 1981) and gastrin releasing peptide (Yamaguchi et al., 1985) and neurone specific enolase (NSE) (Bergh et al., 1985; Said et al., 1985; Rode et al., 1985; Dhillon et al., 1985; Linnoila et al., 1988b; Graziano et al., 1989) . Although elevated levels of neuroendocrine (NE) markers have been detected in NSCLC tumours, the expression of more than one NE marker, though common in small cell lung cancer (SCLC) occurs much less frequently in NSCLC (Berger et al., 1981) . Recent immunohistochemical studies have shown the presence of multiple NE markers in 10-20% of NSCLC (Gazdar, 1986; Linnoila et al., 1988b; Berendsen et al., 1989) . The occurrence of NE differentiation in NSCLC tumours is significant not only because it suggests that the major forms of lung cancer represent a continuum of differentiation within a common cell lineage, but also because the response of neuroendocrine NSCLC (NE-NSCLC) to chemotherapy has been shown to be similar to that of SCLC. In vitro drug sensitivity testing of SCLC, NSCLC and NE-NSCLC cell lines has shown that SCLC and NE-NSCLC cell lines are more responsive to cytotoxic drug treatment than non-NE-NSCLC (Gazdar, 1986) . Similarly, several studies have shown that patients with NE-NSCLC show increased response to chemotherapy compared to patients with non-NE-NSCLC tumours (Mulshine et al., 1987; Gazdar et al., 1988b; Linnoila et al., 1988a; Berendsen et al., 1989; Graziano et al., 1989) .
These findings on drug response show that the clinical behaviour of NE-NSCLC tumours is similar to that of SCLC. A second clinical characteristic of SCLC is the aggressive nature of the disease and its propensity for early and extensive metastatic spread. To further evaluate the clinical significance of NE differentiation in NSCLC, the present study examines the relationship between the expression of NE markers, metastatic spread and survival in surgically operable NSCLC patients.
A panel of neuroendocrine markers has been used to screen for NE properties in a prospective (n = 44) and retrospective (n = 315) collections of NSCLC tumour samples. Markers selected for study include: NSE, an isoenzyme of the glycolytic enzyme enolase which has been identified as a marker for SCLC and other NE tumours (Schmechl et al., 1978; Marangos et al., 1982) ; creatine kinase BB (CK-BB) found in large amounts in the brain, gastro-intestinal tract and SCLC ; chromogranin-A, a protein which stabilises the intragranular matrix of neurosecretory/ dense core granules (DCG) (Bishop et al., 1988) ; protein gene product 9.5 (PGP 9.5), a ubiquinated protein (Wilkinson et al., 1989) reported to be present in nerves, neuroendocrine tissues and associated benign and malignant tumours ; bombesin-like peptides and neurotensin, hormones often elaborated by SCLC and other neuroendocrine tumours (Moody et al., 1981; Hamid et al., 1987) ; synaptophysin, a membrane protein isolated from presynaptic vesicles of bovine neurones, and reported to be present in the normal neural and neuroendocrine tissues and tumours associated with them (Gould et al., 1986) ; and finally we have examined the expression of the cell surface protein NCAM (neural cell adhesion molecule), which is recognised by the monoclonal antibody UJ-13A (Patel et al., 1989; Allan et al., 1983 (Hermanek et al., 1987 Normal tissues A range of normal tissues were included in the study to assess antibody specificity for neuroendocrine tissues. These included pancreas, small and large bowel, testis, thyroid, pituitary, adrenal gland, adult and foetal lung, bronchus, kidney, muscle, brain, spinal cord, spleen and lymph node which were obtained from surgically resected specimens and fresh post-mortem cases. These were fixed in neutral buffered formal saline, processed and embedded in paraffin wax.
Antibodies
The majority of antibodies were obtained from commercial sources as detailed in Table I . UJ-13A was generously donated by Dr John Kemshed (ICRF Oncology Laboratory, Institute of Child Health, London, UK) and was used only on frozen material. Commercially available antibodies were selected on the basis of high immunogen purity thus limiting the potential for cross reactivity (see Table I ). Each of the primary antibodies was specifically titrated for the study using control tissue. Dilutions were considered optimal when each of the antibodies specifically stained SCLC, carcinoid tumours, pulmonary neuroendocrine cells, and/or, pancreatic islets, or nerves within the control tissue sections. In addition to normal tissue reactivity, antibody specificity was confirmed for each antibody by blocking studies with the immunogen concerned, except for antibodies to synaptophysin, PGP 9.5, UJ-13A and chromogranin-A.
The anti-synaptophysin antibody, although commercially marketed as suitable for formalin fixed paraffin wax embedded tissues, showed much background staining. This contrasted with acetyl alcohol fixed paraffin wax embedded material, where there was good delineation of NE tissues. Hence this antibody was restricted for use on acetic alcohol fixed material.
The anti-PGP 9.5 antibody also stained renal tubular epithelium and other non-neuroendocrine tissues. Other studies have also detected PGP 9.5 in a variety of non-NE tissues (Wilson et al., 1988) and hence this marker was excluded from the rest of this study.
Immunohistochemistry A brief outline of the method for immunostaining is as follows: 5 gsm sections were dewaxed in xylene, rehydrated in graded alcohols to distilled water. Endogenous peroxidase was blocked by pretreatment of all sections in 10% hydrogen peroxide for 10min. Sections were treated sequentially with (i) bovine serum albumin for 10min; (ii) primary antisera appropriately diluted (see Table I ) in Tris buffered saline (TBS), at 4°C overnight for 17 h; (iii) three 10 min washes in TBS; (iv) biotinylated swine anti-rabbit serum diluted (1/200) for 30 min; (v) three 10 min washes in TBS; (vi)-avidin-biotin peroxidase conjugate complex (Dakopatts, UK) for 30min followed by washing in TBS for a further 10 min. The peroxidase colour was visualised by incubation in diamino benzidine for 5 min, followed by washing in TBS for 10 min. Slides were lightly counterstained with Harris's haemotoxylin. In addition to the aforementioned specificity controls, substitution of each primary antiserum with normal rabbit serum or TBS was carried out for every tumour examined.
The staining of tumours was assessed using light microscopy, and positivity was scored on a scale of + 1 to + 3, where + 1 was weak but greater than background staining and + 3 intense staining. Tumours were recorded as positive for individual markers when positive staining was identified in at least 5% of the section. The staining of keratin pearls, seen occasionally in well differentiated squamous cell carcinoma, was considered non-specific. Statistical analysis Correlation between categorical variables was assessed using chi-squared tests. Survival curves were compared using the log rank test (Peto et al., 1977) . Multivariate analysis using
Cox's proportional hazards regression model (Tibshirani, 1982 ) and a forward stepwise variable selection procedure was employed to identify factors of independent prognostic importance. The primary endpoint used was death from lung cancer, although analysis according to all-cause mortality was also carried out.
Results
Antibody reactivity with normal tissues The pattern of antibody reactivity with normal tissues is summarised in Table II . It can be seen that with the exception of anti PGP 9.5 antiserum, the antibodies selected for the study are specific for neuroendocrine tissues. (Figure lb) ; 26% of TI, 31% of T2 and 43% of T3 cases (Figure lc) . A significant association exists between N-stage and neuroendocrine positivity (2 = 6.1 on 2 d.f., P = 0.05) (Figure la) . The highest proportion of NE positive cases were staged as N2, but a test for trends of increasing NE positivity with N stage was also statistically significant (X2 test for linear trend, x2 = 5.2 on 1 d.f., P = 0.02). Similarly, a significant association exists between overall disease stage and neuroendocrine positivity (Q = 6.3 on 2 d.f., P = 0.04) (Figure lb) . A similar trend is apparent for T stage ( Figure lc) ; however, these data do not reach statistical significance (Q = 3.6 on 2 d.f., P = 0.17). Log rank analysis of each of the individual markers was carried out but none showed significant difference in survival between patients positive or negative for the markers. Similarly, there was no difference in survival between patients with and without NE-NSCLC (X = 0.38 on 1 d.f., P = 0.54). (Bergh et al., 1985; Said et al., 1985; Rode et al., 1985; Dhillon et al., 1985; Linnoila et al., 1988b; Graziano et al., 1989) . The detection of CK-BB immunoreactivity in 67% of SCLC and 14% of squamous cell tumours compares well with previous radioimmunoassay data (Ruberry et al., 1983) . While several studies have failed to detect bombesin like immunoreactivity in NSCLC using immunohistochemistry Hamid et al., 1987) , a recent study by Linnoila et al., 1988b , reported the immunohistochemical detection of bombesin like immunoreactivity in 13% of NSCLC. In the present study, 8% of NSCLC tumours showed bombesin like immunoreactivity.
The presence of neurotensin in adenocarcinomas has also been previously described (Dammrich et al., 1988) . The additional detection of neurotensin in squamous cell and large cell undifferentiated carcinomas in the present study, possibly reflects the larger numbers examined. NCAM positivity was observed in frozen tumour material in one of three carcinoid tumours and in 20% of non-SCLC cases. A study by Gatter and Dunnill, 1985, also Since cell differentiation is characterised by the coordinated expression of cell specific groups of genes, the detection of multiple NE markers within a single neoplasm is likely to delineate NSCLC tumours with a true endocrine profile. In the present study the expression of two or more markers identified all but one of the carcinoid tumours and all SCLCs and, therefore, was taken to define the neuroendocrine phenotype. Using this criterion, 30% of NSCLC tumours in both the retrospective and prospective group were found to be neuroendocrine. These results compare well with those reported previously (Linnoila et al., 1988b; Graziano et al., 1989; Berendsen et al., 1989) . Importantly, tumours positive for two or more markers in our consecutive surgical series were associated with nodal involvement, particularly N2 disease. Furthermore, such tumours were associated with an increased likelihood of stage II disease. These findings indicate that NE-NSCLC tumours appear to be more frequently highly metastatic than non-NE tumours and supports the contention, based on chemosensitivity studies, that the clinical behaviour of these tumours is similar to that of SCLC. The findings of this study also show that NE differentiation in NSCLC is of no prognostic significance with respect to survival. The ongoing prospective study initiated in parallel with this retrospective investigation will determine further whether the presence of NE markers identifies disease with an inherently more aggressive natural history than that of non-NE-NSCLC. 
